Category Archives: Regenerative Medicine

The buzzy field of synthetic biology aims to create complex life from customized DNA, a goal that has been decades in the making.

Now, researchers have taken a major step toward that sci-fi ambition: For the first time ever, a team has successfully mixed and matched mammal chromosomes, large-scale changes that would ordinarily take millions of years to achieve naturally via evolution. Such research might shed light on diseases stemming from chromosomal abnormalities in people, according to a new study published in Science.

HERE'S THE BACKGROUND Genetic mutations normally help rearrange chromosomes over millions of years. For example, the human genome is normally divided into 23 pairs of chromosomes, with each parent supplying a set of 23 chromosomes. But the gorilla genome consists of 24 pairs. Thats because two sets of chromosomes fused in human ancestors, while they remained separate in gorilla ancestors.

Rearrangements of chromosomes usually happen roughly every 1.6 per million years in primates and every 3.2 to 3.5 per million years in rodents. But synthetic biologists are exploring ways to engineer these changes on a far shorter timeline certainly within a human lifetime.

"An ultimate goal of synthetic biology is to generate complex multicellular life with designed DNA sequences," says study co-author Li-Bin Wang, a cell biologist at the Beijing Institute for Stem Cell and Regenerative Medicine.

To create such organisms, she explains, its necessary to carry out the sort of large-scale manipulation proven possible in this experiment.

Previously, researchers succeeded in engineering chromosomes in yeast, a fungus that makes our beloved sourdough and beer possible. But until now, no one had accomplished it with mammals.

The problem was that molecules are normally bound to DNA that help control which genes are active or inactive, a phenomenon known as genomic imprinting. Past chromosome-modifying experiments in mammal cells often disrupted the patterns of this genomic imprinting in mammal cells, which in turn prevented growing live animals from these cells.

Over the past few decades, scientists have blasted cells with chemicals or radiation to cause massive shifts in chromosomes. But now, synthetic biologists want to make these changes with a more precise, repeatable method.

What they did In the new study, researchers in China worked with mice, which normally have 20 pairs of chromosomes. They performed the experiment on embryonic stem cells from unfertilized mouse embryos, each of which only contained one set of chromosomes.

The scientists found that getting rid of three imprinted regions can kick off genomic imprinting in embryonic stem cells. As a result, they could fuse chromosomes in these cells and allow them to grow into embryos.

In some stem cells, the researchers fused two medium-sized chromosomes the tail of number 4 to the head of number 5, leading to cells dubbed 4+5. In others, they fused the two largest chromosomes, numbered 1 and 2. They did this by either sticking the tail of chromosome 1 to the head of chromosome 2 (for cells dubbed 1+2) or fusing the tail of chromosome 2 with the head of chromosome 1 (cells that were called 2+1).

The scientists then injected these altered embryonic stem cells into mouse egg cells, where they could develop into embryos in surrogate mouse mothers. These each had only 19 pairs of chromosomes, one pair fewer than natural mice. While mouse pregnancy lasts around three weeks, the genetic tweaking only took a few days magnitudes quicker than actual evolution.

The technique used by Wangs team wont be used to create mutants, it seems.MARK GARLICK/SCIENCE PHOTO LIBRARY/Science Photo Library/Getty Images

What they found The scientists observed that the 2+1 cells acted abnormally, so the embryos died only about 12 days into development. Compared to both typical mice and the 4+5 mice, the 1+2 cells developed into pups that grew into larger, more anxious, and slower-moving adults.

Only the 4+5 mice were able to produce offspring with standard mice, but at a much lower rate than typical lab mice. Still, they were able to pass on their fused chromosome to their rodent babies. This win has major ramifications for future research.

"Our chromosome fusion technology adds to the toolbox of synthetic biology," Wang says.

Whats next Moving forward, Wangs team may create mice with chromosome fusions to better understand diseases associated with chromosome abnormalities, such as infertility and childhood leukemia, Wang says.

You may be wondering: Can researchers use this technique to forge new species? Unfortunately for sci-fans, Wang says its intended to study how chromosomes evolve in nature, rather than creating some sort of mutant creature.

LEARN SOMETHING NEW EVERY DAY.

More:
Scientists just bypassed millions of years worth of evolution in mice - Inverse

Requesting Input: NIAMS Strategic Plan 20252029

NIAMS is updating its Strategic Plan to help guide the research it supports. The new plan will cover fiscal years 20252029 and will focus on cross-cutting thematic research opportunities where the Institute can be best positioned to make a difference in the lives of all Americans. NIAMS invites feedback from researchers in academia and industry, health care professionals, patient advocates and health advocacy organizations, scientific or professional organizations, federal agencies, and interested members of the public. Professional societies and patient organizations are strongly encouraged to submit a single response that reflects the views of their membership as a whole. Responses can be submitted on this websiteand are due November 30, 2022.

NIAMS is operating under the FY 2022 Consolidated Appropriations Act. The interim funding plan for research and training grants represents the most current information as of the date cited on the web page.

Get the latest public health information from the Centers for Disease Control and Prevention, and the latest funding opportunities and research news from the National Institutes of Health (NIH). Additional news and resources include:

On September 22, 2022, watch NIH videocast, Cartilage Preservation and Restoration for Knee Osteoarthritis. NIAMS is planning this roundtable to engage stakeholders in discussing challenges, gaps, and opportunities regarding regenerative medicine approaches for cartilage preservation and restoration in knee osteoarthritis and where and how NIAMS could play a role and move the field forward.

Mariana Kaplan, M.D., Chief of the Systemic Autoimmunity Branch in the NIAMS Intramural Research Program, aims to stop the immune system from harming the cells it is supposed to defend. Her unique expertise is being applied to various disease areas, including autoimmune diseases, especially systemic lupus erythematosus, or lupus, Sjogrens syndrome, inflammatory illnesses, and COVID-19.

Researchers supported in part by NIAMS found that a molecule, called Lac-Phe, produced during exercise by various mammalsincluding peoplereduces food consumption and obesity in mice.

The NIAMS STAR program provided two funding supplements to early-career stage investigators who have renewed their first NIAMS-funded R01 grant:

Erika Geisbrecht, Ph.D., is a Professor of biochemistry and molecular biophysics at Kansas State University in Manhattan. She leads a NIAMS-supported research project using the Drosophila model to determine mechanisms that prevent protein aggregation, and ultimately cellular degeneration, in muscle.

Corey Neu, Ph.D., is the Donnelly Family Endowed Professor of mechanical engineering at the University of Colorado at Boulder. He leads a NIAMS-funded research project to establish a noninvasive imaging method of measuring cartilage strain to predict osteoarthritis development.

The AMP BGTC announced that it has selected 14 rare disease candidates, including two rare orthopaedic conditionsfibrodysplasia ossificans progressiva and mucopolysaccharidosis IVA (MPS, IVA, Morquio A Syndrome). In addition, a new request for proposals has been issued for clinical trial proposals directed to one of the 14 bespoke indications.

The U.S. Food and Drug Administration (FDA) approved Opzelura (ruxolitinib) cream for the treatment of nonsegmental vitiligo in adult and pediatric patients age 12 and older. Opzelura is a topical Janus kinase (JAK) inhibitor.

See more here:
NIAMS Update, Issue 4, 2022 | NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

An American Heart Association fellowship will allow a Binghamton graduate student to further her research in developing 3D heart models. Natalie Weiss is interested in the pharmaceutical implications for treating cardiac fibrosis, an abnormal thickening and scarring of heart tissue that is common with many types of heart diseases and conditions.

The AHA is such a big and well-respected organization, so it is a nice validation to see that they value my research and ideas, said Weiss, a biomedical engineering doctoral student from the Thomas J. Watson College of Engineering and Applied Science who received a competitive two-year pre-doctoral fellowship.

Weiss conducts her work in the lab of Tracy Hookway, assistant professor of biomedical engineering. The team uses cell culture, 3D modeling of stem cells and live imaging of tissue for regenerative medicine therapy.

Natalie has been a huge asset to my lab, Hookway said. Shes incredibly intelligent and very ambitious, and shes not afraid to ask questions.

Weiss research involves creating working models of human hearts and then testing various drugs and therapies with the goal of resolving or improving cardiac fibrosis. She uses stem cells derived from human skin to make heart muscle cells and then combines them with proteins, sugars and a gel polymer, which is then piped into a 3mm donut ring mold (of sorts). The process takes about a week and a half, but once the cells are added to the mold, the ring forms overnight into a simplified, beating human heart model.

By testing on these models, it saves time, money and testing on animals, Weiss said, adding that she often has 40 rings going at a time. What Im hoping to do, once the models are a little more advanced, is replicate the stiffness of cardiac fibrosis in the model and then test a couple of drugs and see if it responds in a positive way.

As a high school student in East Meadow, Long Island, Weiss knew she was interested in the medical field. She volunteered in an emergency room and got her EMT certification.

Ive also always loved problem solving taking things apart and figuring out how they worked, she said. I wasnt aware I could put those two interests together until a biomedical engineering major kept popping up again and again as I was researching college programs.

She received her undergraduate degree in biomedical engineering at Stony Brook University in 2019, and then started her graduate career at Binghamton that fall. She selected the program because she was impressed with Hookway, who would become her advisor.

I wanted someone who I can connect with, Weiss said. Dr. Hookway really seemed like someone who would advocate for her students, so I knew she was going to care about my progress and help me out.

Once Weiss completes her doctorate, she hopes to complete a post-doctoral fellowship and then become a professor and run her own research lab.

This article was originally published in Discover-e.

Read the rest here:
Heart Association fellowship to support research - Binghamton

We drove slowly down the congested street toward my daughter's new dorm last week, past the throng of local high school students ambling toward their first day of the academic year. It was a sunny, warm California morning. By midday, the temperature would rise to 106 degrees Fahrenheit. The next day, it would hit 109F. The forecast for Houston today is near 100. For Las Vegas, 101. For Phoenix, 102, with a "real feel" of 108. For New Orleans, it's only 85 with heavy rain. Across the country this month, accelerating climate change has meant that students from kindergarten to college are returning to school in some of the most extreme weather on record. Who can think, let alone learn, in conditions like that?

As a northeasterner, I've long associated back to school with the cooler, brisker days of pumpkin spice season. I knew college would be a different experience for my west coast-bound daughter. Yet I hadn't considered just how different until we walked around her campus that first day, where a handful of students who were outside braving the weather staggered around like zombies. The buildings were all generously air conditioned, but just getting around felt like an endurance test, one designed to sap energy and concentration.

Want more health and science stories in your inbox? Subscribe toSalon's weekly newsletter The Vulgar Scientist.

We've known for a long time that heat is brutal on the body.

"In extreme heat, the body goes into shock," saysRosmy Barrios, MD, a medical advisor forHealth Reporter and a regenerative medicine specialist. "Both students and teachers may feel dizzy and irritable. This is due to increased blood flow to dilated blood vessels and fluid loss due to intense sweating."

"In such conditions, it is difficult to learn and concentrate."

"When the body's internal temperature rises above the normal limit," she continues, "you start to sweat more and more intensively, dizziness increases, and you feel extreme fatigue. The symptoms resemble a fever, and almost everyone who has experienced it knows that mental work can be impossible in such a state."

Heat also affects your mind in all kinds of unique ways. A 2018 study reported inFrontiers in Physiology notes higher temperatures appear to lead to slower reaction times, and diminished attention and retention. As far back as as 2003, the International Journal of Hyperthermia was looking at "the effects of heat stress on cognitive performance" in the workplace, and reporting that while "simple tasks are less vulnerable to heat stress," more complex ones, "such as vigilance, tracking and multiple tasks" you know, like the functions involved in learning "show signs of performance decrement."

And, in case you missed that 2017 issue of the Journal of Environmental Economics and Management that covered "the effects of summer heat on academic achievement," other research shows a measurable downtick in math and English test scores on days above93 degrees, against scores on days ten degrees cooler.As Joe Allen, director of theHarvard Healthy Buildings Program, told NPR in 2018, "There's evidence that our brains are susceptible to temperature abnormalities. It's a little bit akin to the frog in the boiling water a slow, steady largely imperceptible rise in temperature, and you don't realize it's having an impact on you."

Working indoors in cooler environments helps ameliorate some of the problems, of course, but the physiological effects of heat don't immediately disappear the moment a student walks into some full blast AC. And for those don't have that luxury, the heat can profoundly affect academic performance. Unsurprisingly, it's lower income kids and Black and Hispanic kids who bear the worst consequences.

Indeed, after a global 2020 study in Nature Human Behavior found a correlation between higher temperatures and lower test scores, the authors noted another finding a profound racial gap in whose scores were affected. Researcher R. Jisung Park told the New York Times that the results "seemed to reflect the fact that minority students are less likely to have air-conditioning at school and at home... causing a gradual and cumulative toll on those students' ability to absorb their lessons." Writing for Grist last year,Nathanael Johnson reported that "Most school districts need major building-system repairs, like heating, ventilation, and air conditioning updates. Some of those are schools... that have never had air conditioning before."

Climate change poses other serious potential hazards to education, if you're willing to connect the dots. The Association for Psychological Science warns of a link between rising temperatures and violence. It estimates that each 1 degree Celsius increase in average temperature (roughly 2 degrees Fahrenheit) "a fairly conservative estimate of climate change in the following decadeswill likely yield a 6% increase in violent crime rates." The United Nations further warns that because of factors like displacement, girls and women will bear the brunt of that violence. And after you've spent a day driving around in a California town where there's a wildfire warning and a flooding warning at the same time (because climate change isn't just about heat), you understand intimately the threat of abrupt evacuation that a growing number of us face. Worried about school safety now? Anybody think turning up the temperature will make it better?

Climate change is also eroding our sleep cycles, which is terrible for everyone but affects students uniquely, accounting in some studies for nearly 25% of the variation in academic performance.

"45% of respondents said their feelings about climate change negatively affected their daily life and functioning."

Then there's the omnipresent and very real anxiety our kids feel about this overheated planet we're leaving them. A 2021 Lancet study of 10,000 children and young people around the world found that "59% were very or extremely worried" about climate change and "45% of respondents said their feelings about climate change negatively affected their daily life and functioning."

"They know, and they're angry," says Heather White, activist and founder of the nonprofitOne Green Thing and author of the book of the same name. "They feel abandoned, for lack of better word. And they're understandably worried."

What can we do? Tim Mohin, who has worked with the Senate and Environmental Protection Agency on policies like the Clean Air Act and is now the chief sustainability officer for Persefoni AI says that schools need to adjust to the reality of climate in much the same way that have to the threat of shootings. "Why are we starting school in August?" he asks. The heat isn't just about class time and test taking either, he notes, citing the new challenges of maintaining school athletics in untenable weather. We're beginning to recognize that changing the hour school starts could help our kids have a better educational experience; it's time to do the same with the school calendar.

We can invest in realistic initiatives to cool things down. "There are some interesting studies that having trees in urban areas can actually reduce temperature by nine degrees Fahrenheit," says Heather White. "Supporting urban forests and urban parks is really important. Climate change is a public health issue. And it's a children's health issue. We need to have these these options in order to create safer places for students to learn."

If we want our kids of all ages to have a positive school experience one that includes being well rested, being as free from anxiety and the threat of violence as possible, being able to play sports, and simply being able to concentrate and remember we have to acknowledge the role of climate change in all of those things. Getting an education is hard enough; extreme weather is only making it that much harder. In my daughter's college town, she's currently finishing her first week of classes. And she tells me it's "only" going to be 99 degrees Fahrenheit today.

Read more

about going back to school in America

The rest is here:
Climate change is making the new school year harder in all kinds of ways - Salon

Westford, USA, Aug. 25, 2022 (GLOBE NEWSWIRE) -- As the world increasingly becomes connected and people live longer, surgery and medical procedures become more complex. Surgery, one of the most common medical procedures, is now estimated to use over 1 million surgical tools each year. In order to meet the rising demand for surgical tools, surgeons are turning to biomaterials as a key component in their procedures. The main reason for this growth of the global biomaterials market is the increasing demand for novel biomaterials in various sectors such as automotive, aerospace, construction, and medical applications.

The growing demand for biomaterials has led to several companies developing unique biomaterials specifically for surgery. Some of the most well-known biomedical materials including polypropylene microspheres, chitosan hydrogel, and alginate matrix were pioneers in the field of biomaterials. Today, there are numerous new types of biomaterials being developed and marketed for a variety of medical applications, such as wound healing and orthopedic surgery. Global biomaterials market is expanding rapidly due to increasing public awareness of the benefits of using these materials and growing demand from pharmaceutical and medical device companies.

SkyQuest has published a report on global biomaterials market. The report provides a detailed market analysis, which would help the market participant in gaining is insights about market forecast, company profiles, market share, pricing analysis, competitive landscape, value chain analysis, porters five, and pestle among others.

Get sample copy of this report:

https://skyquestt.com/sample-request/biomaterials-market

Demand For Biomaterials in the Healthcare Industry will Grow by 53% Over the Next Five Years

The demand for biomaterials market in the healthcare industry is growing rapidly, according to SkyQuest study. We studied global economic data and discovered that the demand for biomaterials in the healthcare industry will grow by 53% over the next five years. In 2021, 10.7 million patients used some kind of biomaterials across different applications such as wound care, tissue implant, surgeries, and medical devices, among others. This rising demand is impacting not only hospitals and clinics, but also diagnostic laboratories and pharmaceutical companies.

Most biomedical materials are manufactured from organic materials such as skin, bone, cartilage, and tendons. While these materials can be derived from a variety of sources, synthetic biomedical materials are often cheaper and more readily available. However, synthetic biomedical materials do not have the same properties as natural materials, which means they may not be as effective when used in medical treatments. Biologically based biomaterials are more effective because they can mimic the properties of natural tissues. Their potential benefits make them a highly desired commodity in the healthcare industry across the global biomaterials market. In 2021 alone, sales of artificial joints were worth $2.2 billion, while sales of regenerative medicine products such as stem cells and platelet-rich plasma were estimated to be worth $8.8 billion in the same year.

SkyQuest has done a detailed study on global biomaterials market and prepared a report that also covers current consumer base, potential demand for products, demand analysis by category and volume, expected growth, prominent growth factors, market dynamics, trends, opportunities, and innovation, among others.

Browse summary of the report and Complete Table of Contents (ToC):

https://skyquestt.com/report/biomaterials-market

Top 4 Biomaterials in Global Market

1. Stem cells- Stem cells have become one of the most promising areas of biomaterial research because they can be modified to create a wide variety of tissue types, including cartilage, skin, and bone.

2. Chitosan- Chitosan is a natural polymer found in creatures ranging from crabs to shrimp, and it is prized for its ability to form strong and durable bonds with other materials.

3. Polycaprolactone- Polycaprolactone is a modified form cellulose that has been shown to have many potential biomedical applications, including as a replacement for hard tissues like heart valves and bones.

4. Mesenchymal stem cells- Mesenchymal stem cells (MSCs) are adult cells found in the connective tissue and skeletal muscles of mammals. MSCs have characteristics that make them especially effective at repairing tissues damaged by disease or injury, which is why they are commonly used in studies on regenerative therapies.

Recent Advancements in Biomaterials Market

Successful applications of biomaterials in disease treatment have made them a preferred choice for many medical procedures. For example, use of biomaterials for artificial heart valves has revolutionized the way these devices are operated and prevented heart failure in patients.

In addition, various biomaterials are being developed for use in regenerative medicine. For example, researchers in the global biomaterials market are exploring the possibilities of using nano-sized polymers to promote the growth of new tissue in injured or damaged tissues. This approach may prove to be an effective way to restore function to damaged organs and limbs.

Biomaterials are also being used to create new types of prosthetic devices. For example, doctors are currently testing a new type of artificial hip that uses a biocompatible material as its main component.

Speak to Analyst for your custom requirements:

https://skyquestt.com/speak-with-analyst/biomaterials-market

SkyQuests report on global biomaterials market would help you in gaining insights about current developments and its impact on the overall market growth, pricing, demand and supply, change in growth strategies of existing players, among others. Also, the report would help in understanding how the market value is changing and affecting the forecast revenue over the period.

Top Players in the Global Biomaterials Market

Related Reports in SkyQuests Library:

Global Cell Therapy Market

Global Flow Cytometry Market

Global Bioinformatics Market

Global Synthetic Biology Market

Global Biopharmaceutical Analytical Testing Services Market

About Us:

SkyQuest Technologyis leading growth consulting firm providing market intelligence, commercialization and technology services. It has 450+ happy clients globally.

Address:

1 Apache Way, Westford, Massachusetts 01886

Phone:

USA (+1) 617-230-0741

Email:sales@skyquestt.com

LinkedInFacebookTwitter

The rest is here:
Global Biomaterials Market to Reach Value of $372.7 Billion by 2028 | Demand For Biomaterials in the Healthcare Industry will Grow by 53% Over the...

Pink Porcelain Anatomical Heart 3d illustration 3d render

This story on artificial hearts is part of an extended series on Regenerative Medicine. For other stories on this topic see williamhaseltine.com and search for Regenerative Medicine. My definition of Regenerative Medicine is any medical modality that returns us to normal health when we are damaged by disease, injured by trauma, disadvantaged by birth, or worn by time. Modalities include: chemicals, genes, proteins and cells used as drugs, gene editing, prosthetics, and mind-machine interfaces.

Heart disease affects approximately 82.6 million people in the United States and is a leading cause of death among both men and women. One solution for those suffering from advanced heart failure is heart transplantation. Unfortunately, there is currently a nationwide shortage of human donor hearts. Scientists have attempted to create artificial hearts or use pig organs in lieu of human hearts for transplantation surgeries. However, current methods to produce artificial hearts are generally unsuccessful and the use of pig organs for transplants can lead to serious infections.

Now, a group at Harvard University is tackling this issue through a new, innovative method of growing artificial hearts. By building an artificial structure and implanting cardiac cells, researchers were able to grow the cardiac cells in a pattern that mimicked the natural organization of muscles in the heart. This study serves as a significant stepping stone toward developing artificial hearts that are fully functional.

The heart is largely made from muscles arranged in a helical fashion. When the heart contracts, its helically-patterned muscles engage in a twisting motion to push blood out of the heart. In fact, this helical patterning is predicted to be a crucial characteristic of healthy, functioning hearts. Many individuals who suffer from cardiac dysfunction also exhibit abnormal muscular patterning.

Figure 1: Human hearts engage in a twisting motion to pump blood through the body.

In the past, several studies have attempted to grow artificial hearts with helical patterning by using 3D printers. These studies have largely been unsuccessful because 3D printers are unable to achieve the tiny details of the hearts structure within a reasonable amount of time. For instance, a 3D printer could take hundreds of years to print even a small component of the hearts structures with enough detail for cells to grow in the correct patterns.

So, how did scientists at Harvard University achieve this feat?

Knowing that a simple 3D printer has significant limitations, Chang et al. turned towards a different technique: fiber-spinning. Fiber-spinning is a method that uses similar materials to 3D printers but can produce much finer, high-resolution structures.

Traditionally, materials are heated and extruded from a tiny hole to create singular fibers at a microscopic scale. The fibers can then be collected or processed to form 3D structures.

Figure 2: Fiber-spinning involves extruding polymers from a tiny hole to create microscopic fibers.

Fiber-spinning can create structures with very high resolutions. However, traditional methods of fiber-spinning are often imprecise and would not be able to form the consistent helical patterns of the heart. This prompted Chang et al. to engineer a new method of fiber-spinning that would not only allow them to create the hearts 3D structure at a microscopic scale but would also be precise enough to form the hearts helical patterning.

Chang et al. created a new fiber-spinning device with two major design features. First, instead of simply extruding the material haphazardly in one direction, the fiber-spinning device contains a spinneret that spins at high speeds. When the heated material is pushed into the device, the fibers are then extruded through a small hole in the side of the spinneret. This causes the fibers to collect in a cloud around the device.

Chang et al.s second innovation was to include a strong stream of air at the top of the spinneret that could align the fibers to resemble the striations of muscles. From this, Chang et al. could collect the fibers at an angle, ultimately creating the helical patterns of cardiac muscle.

Figure 3: Chang et al. used a spinneret and focused airstream to create 3D structures of the heart.

Using this method, Chang et al. was able to create 3D frames that resembled human heart ventricles. When the frames were seeded with human cardiac cells, the resulting tissues maintained the helical patterning of the frame.

Surprisingly, after 3 to 5 days of growing cardiac cells on the 3D frames, Chang et al. observed spontaneous contractions that resembled the natural activity of the human heart. This indicated that Chang et al.s model ventricles could be used to study how muscle patterning affects heart function.

To investigate this question, Chang et al. created model ventricles with helically aligned cells as well as ventricles with abnormal, circumferentially aligned cells.

Figure 4: Chang et al. created model ventricles with helically aligned cells and circumferentially ... [+] aligned cells.

The researchers then suspended both model ventricles in a liquid containing fluorescent beads. By tracking the displacement of the beads, Chang et al. could determine how many were pumped through the ventricles at a time. This strategy allowed the researchers to calculate the overall volume of liquid the model ventricles could pump.

After testing both the helically patterned ventricle and the abnormally patterned ventricle, Chang et al. found that the helically patterned ventricle was able to pump significantly higher volumes of liquid. This demonstrated that abnormal alignment of cardiac cells does, in fact, decrease the hearts ability to function.

Finally, not only was Chang et al. able to create model heart ventricles that could contract, but by using their innovative fiber-spinning method, the researchers were able to recreate all four chambers of the heart. These individual chambers were then assembled to ultimately create a full-sized model of the human heart.

Figure 5: Chang et al. successfully created all four chambers of the heart to assemble a full-sized ... [+] model.

Overall, this study represents significant progress in our ability to create a fully functional artificial heart. While more work must be done to expand functional model ventricles into full-scale heart models, this study demonstrates real promise for the use of innovative fiber-spinning techniques for complex whole-organ formation.

Link:
How To Mend A Broken Heart - Forbes

The first of approximately 97 patients with classical Hodgkin lymphoma (cHL) has been administered the combination of TT11 and nivolumab (Opdivo) in the phase 1b ACTION study (NCT05352828).1

TT11 is an experimental autologous CD38-chimeric antigen receptor (CAR) T-cell therapy that is being developed for the potential treatment of relapsed or refractory cHL as a single agent and in combination with other therapies. The agent had been granted a regenerative medicine advanced therapy designation by the FDA and the PRIME scheme by European Medicines Agency.

Initiation of this phase 1b clinical trial marks an important milestone for our autologous CD30- CAR T program as we now have the opportunity to evaluate TT11 in combination with nivolumab as a potential second-line treatment for relapsed or refractory classical Hodgkin lymphoma, stated John Ng, chief technology officer and acting chief operating office and of Tessa Therapeutics, in a press release.

Dosing in the study comes after single-agent results were reported from the phase 2 CHARIOT study (NCT04268706). In heavily-pretreated patients with cHL, promising efficacy and tolerable was shown with TT11 monotherapy. The overall response rate observed was 71.4% with a complete response rate of 57.1% In terms of safety, the most common toxicities were hematologic toxicities.2

Data from our ongoing clinical program investigating TT11 as a monotherapy treatment for later lines of classical Hodgkin lymphoma has demonstrated the CAR T therapy to be safe with promising measures of efficacy. We now welcome the opportunity to capitalize on this clinical progress by investigating TT11 as a second-line combination therapy, which offers the opportunity to greatly increase the patient population who could potentially benefit from this course of care, added Ng.1

In the multicenter, open-label, single arm ACTION study, patients will receive 4 cycles of TT11 at 2 x 108 cells/m2 in combination with nivolumab 480 mg or 6 mg/kg 4 times per week, fludarabine 30 mg/m2/day for 3 days, and bendamustine 70 mg/m2/day for 3 days after a successful leukapheresis to produce CD30 CAR T cells.3

The primary end point being explored in the study is the safety of autologous CD30 CAR T cells determined by dose-limiting toxicities. The secondary end points of the study include anti-tumor activity, overall response rate, duration of response, and progression-free survival. Other outcome being investigated include overall survival and pharmacokinetics.

Male or female patient aged 12 years or older are eligible to enroll if they have relapsed/refractory cHL following failure on standard frontline therapy, at least 1 measurable lesion, and adequate hematologic, renal, hepatic function and other laboratory tests. Patients are required to have an ECOG performance status of 0 or, a life expectancy of > 12 weeks, and no active infection at the time of screening.

Patients are excluded from the study if they have received prior treatment with salvage therapy for relapsed/refractory cHL, investigational CD30 CAR T cells. Moreover, patients receiving other investigational therapies, live vaccines, or immunosuppressive agents are not eligible for the study. Comorbidities that may interfere with study treatment and hypersensitivity to study drugs are also mentioned in the exclusion criteria.

The ACTION study is actively recruiting patients with relapsed/refractory cHL at study sites in California, Florida, North Carolina, and Texas.

REFERENCES:

1. Tessa Therapeutics doses first patient in phase 1b clinical trial investigating TT11 in combination with nivolumab for the treatment of relapsed/refractory classical hodgkin lymphoma (cHL). News release. August 17, 2022. Accessed August 18, 2022. https://bit.ly/3AteZem

2. Tessa Therapeutics announces positive data from phase 2 trial of autologous cd30-car-t therapy (TT11) in relapsed or refractory classical hodgkin lymphoma at 2021 ASH Annual Meeting. News release. August 14, 2021. Accessed August 18, 2022. https://bit.ly/3Qy0OKL

3. Phase 2 study evaluating autologous CD30.CAR-T cells in patients with relapsed/refractory hodgkin lymphoma (CHARIOT). Clinicaltrials.gov. Updated April 5, 2022. Accessed August 18, 2022.

See original here:
Dosing of Novel Autologous CAR T Cells and Nivolumab Begins in cHL Study - Targeted Oncology

DUBLIN--(BUSINESS WIRE)--The "Global Regenerative Medicine Partnering Terms and Agreements 2015 to 2022" report has been added to ResearchAndMarkets.com's offering.

This report is intended to provide the reader with an in-depth understanding and access to Regenerative Medicine trends and structure of deals entered into by leading companies worldwide.

Regenerative Medicine Partnering Terms and Agreements includes:

In Global Regenerative Medicine Partnering Terms and Agreements 2015-2022, the available deals are listed by:

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Regenerative Medicine Partnering terms and Agreements 2015-2022 report provides comprehensive access to available deals and contract documents for over 1600 Regenerative Medicine deals.

Analyzing actual contract agreements allows assessment of the following:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/pu1ymr

Continue reading here:
Regenerative Medicine Partnering 2015 to 2022: Terms and Agreements Entered Into by the Leading Companies Worldwide - ResearchAndMarkets.com -...

image:The ARDD Meeting 2022 will be hosted on August 29 - September 2, 2022 view more

Credit: Insilico Medicine Hong Kong Limited

August 18, 2022 Marco Quarta, Ph.D., will present the latest research on the topic From Single Cell AI-enabled Discovery of Cellular Senescence to Targeted Senolytic Drug Development at the worlds largest annual Aging Research and Drug Discovery conference (9th ARDD). Dr. Quarta is the CEO and Co-founder at Rubedo Life Sciences.

Marco co-founded and leads Rubedo Life Sciences driving its mission to develop treatments for age-related diseases and extend healthspan by selectively targeting pathological cells involved in the biological aging process. As a scientist, he earned a Masters degree in Biotechnology, a PhD in Neuroscience, and post-doctoral training in Aging and Stem Cells Biology in the lab of his mentor Prof. Thomas Rando at Stanford University School of Medicine. He then directed at Stanford/VA Hospital Palo Alto a research team focused on translational medical research in the fields of aging and regenerative medicine. He is backed by over 20 years of research with a track record of scientific publications in top tier journals. Marco is an inventor and entrepreneur, he co-founded and led the international biotech umbrella organization Young European Biotech Network (YEBN), and later joined the European Federation of Biotechnology (EFB) executive board.

Marco Quarta founded and led the biotech company WetWare Concepts in Europe. In California, with the Stanford colleague Prof. Vittorio Sebastiano he also co-founded Turn Biotechnologies based on their work on epigenetic reprogramming of cellular aging, where he served as CSO and he is a Board Director. Quarta sits on the advisory board of the California Institute for Regenerative Medicine (CIRM) Calpoly program in regenerative medicine. He is in the advisory and research board at the Center for Healthcare Innovation (CHI). He is a member of the Paul F Glenn Center for the Biology of Aging Studies at Stanford University. Quarta keeps fostering and championing high standards of compliance, ethics and patient safety in the development of innovative translational therapeutics, putting patients and society at the center of all actions.

The conference proceedings of the ARDD are commonly published in peer-reviewed journals with the talks openly available at http://www.agingpharma.org. Please review the conference proceedings for 2019, 2020 and 2021https://www.aging-us.com/article/203859/text .

Aging is emerging as a druggable condition with multiple pharmaceuticals able to alter the pace of aging in model organisms. The ARDD brings together all levels of the field to discuss the most pressing obstacles in our attempt to find efficacious interventions and molecules to target aging. The 2022 conference is the best yet with top level speakers from around the globe. Im extremely excited to be able to meet them in person at the University of Copenhagen in late summer. said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.

Aging research is growing faster than ever on both academia and industry fronts. The ARDD meeting unites experts from different fields and backgrounds, sharing with us their latest groundbreaking research and developments. Our last ARDD meeting took place both offline and online, and it was a great success. I am particularly excited that being a part of the ARDD2022 meeting will provide an amazing opportunity for young scientists presenting their own work as well as meeting the experts in the field. said Daniela Bakula, Ph.D., University of Copenhagen.

Many credible biopharmaceutical companies are now prioritized aging research for early-stage discovery or therapeutic pipeline development. It is only logical to prioritize therapeutic targets that are important in both aging and age-associated diseases. The patient benefits either way. The best place to learn about these targets is ARDD, which we organize for nine years in a row. This conference is now the largest in the field and is not to be missed, said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine and Deep Longevity.

Building on the success of the ARDD conferences, the organizers developed the Longevity Medicine course series with some of the courses offered free of charge at Longevity.Degree covered in the recent Lanced Healthy Longevity paper titled Longevity medicine: upskilling the physicians of tomorrow.

About Aging Research for Drug Discovery Conference

At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we are expanding with a workshop specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest? To extend the healthy lifespan of everyone on the planet.

About Scheibye-Knudsen Lab

In the Scheibye-Knudsen lab we use in silico, in vitro and in vivo models to understand the cellular and organismal consequences of DNA damage with the aim of developing interventions. We have discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms. These findings suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier and more productive lives.

About Deep Longevity

Deep Longevity has been acquired by Edurance RP (SEHK:0575.HK), a publicly-traded company. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS) solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other expert AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers. https://longevity.ai/

About Endurance RP (SEHK:0575.HK)

Endurance RP is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering. https://www.endurancerp.com/

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

See more here:
Marco Quarta to present at the 9th Aging Research & Drug Discovery Meeting 2022 - EurekAlert

3D Systems announced on August 18 the appointments of Dr. Toby Cosgrove, former President and Chief Executive Officer of the Cleveland Clinic, and Dr. Bon Ku, Director of the Health Design Lab at Thomas Jefferson University.

Dr. Cosgrove and Dr. Ku become the fourth and fifth members of 3D Systems recently established Medical Advisory Board (MAB). The two join former Health and Human Services Secretary Alex Azar, Dr. Stephen K. Klasko, and former U.S. Secretary of Veterans Affairs David J. Shulkin as members of the advisory board.

The primary mission of the board is to provide strategic input, guidance and recommendations for the companys expanding efforts in regenerative medicine.

Dr. Cosgrove has been affiliated with the Cleveland Clinic healthcare system for nearly 50 years. He served as President and CEO from 2004 to 2017 and is currently an Executive Advisor to the Clinic.

As President and CEO, Dr. Cosgrove oversaw a 6 billion USD annual revenue institution comprised of the Cleveland Clinic, over 20 Ohio-based hospitals, family health centres and surgical facilities, as well as Cleveland Clinic affiliates in other U.S. states and internationally.

Dr. Cosgrove was a cardiac surgeon in Cleveland and served as Chairman of the Department of Thoracic and Cardiovascular Surgery from 1989 to 2004 at the clinic. He has performed over 22,000 operations over the course of his career.

Dr. Bon Ku has enjoyed a career as both a practicing medical clinician and as a proponent of using technology-based innovations to solve pressing healthcare challenges. Dr. Ku is the Marta and Robert Adelson Professor of Medicine and Design at Thomas Jefferson University as well as an emergency physician at the Universitys Sidney Kimmel Medical College.

Dr. Ku has used modern technological tools such as virtualisation, digital modelling, prototyping and additive manufacturing. He is the co-founder and Director of Thomas Jefferson Universitys Health Design Lab. The lab works with medical students, researchers and physicians to develop new medical devices and innovative design concepts for the healthcare sector.

The Health Design Lab led by Dr. Ku features a clinical 3D printing and bioprinting lab and is home to the JeffSolves MedTech initiative. This serves as a centre for the incubation and commercialisation of new medical technologies.

Dr. Ku has written a number of peer-reviewed publications focusing on the application of 3D-printed medical devices and digital models to improve surgical outcomes, optimise treatments and make advancements in personalised medicine.

3D Systems President and CEO Dr. Jeffrey Graves said: We are exceptionally pleased to welcome Dr. Cosgrove and Dr. Ku to our Medical Advisory Board. These two professionals have impeccable track records of combining hands-on medical practise experience with a clear passion for utilising innovative approaches and modern technology to transform healthcare outcomes.

Graves continued, saying: Both Dr. Cosgrove and Dr. Ku will be uniquely positioned to advise 3D Systems as we build a world-class regenerative medicine business and pursue 3D printing-based advancements in areas such as accelerated pharmaceutical development, human tissue and organ printing, medical device innovation and personalised medicine.

There have been a lot of acquisitions from major 3D printing companies so far in 2022, with3D Systems among those to have added new strings to its bow. The company recentlyacquired material jetting firm dp polar, while taking over both Titan Robotics and Kumovis earlier in the year.

3D Systems also recently announced a partnership with Fleet Space Technologies, and produced parts for the Alpine F1 team for the 2021 and 2022 seasons.

Want to discuss? Join the conversation on theAdditive Manufacturing Global Community Discord.

Get yourFREE print subscriptionto TCT Magazine.

Here is the original post:
3D Systems announces appointment of Dr. Toby Cosgrove and Dr. Bon Ku as members of its Medical Advisory Board - TCT Magazine